Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q1 2017 · 10-Q
Revenue$116.90M$116.90M+5.3% vs Q1 2016 Net Income$10.49M$10.49M+162.7% vs Q1 2016 EPS Diluted$0.23$0.23+130.0% vs Q1 2016 Gross Profit$14,900,000−29.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flow$41,671,000−1.2% Free Cash Flowderived$21,367,000−10.8% Margins · derivedGross margin12.7%−6.3 pt vs Q1 2016
Operating margin12.8%−6.3 pt vs Q1 2016
Net margin9.0%+5.4 pt vs Q1 2016
ended Mar 31, 2017 · filed May 5, 2017 · 35 d after period end